DC-CIK细胞免疫治疗联合化疗在中晚期非小细胞肺癌治疗中的应用效果分析

Analysis of the effect of DC-CIK cell immunotherapy combined with chemotherapy in the treatment of middle and advanced non-small cell lung cancer

目的:分析DC-CIK细胞免疫治疗联合化疗在中晚期非小细胞肺癌治疗中的应用效果。方法:2017年1月-2018年1月收治中晚期非小细胞肺癌患者98例,随机分为两组,各49例。对照组接受单纯化疗治疗,研究组接受DC-CIK细胞免疫治疗联合化疗治疗,比较两组治疗效果及两年生存率。结果:研究组治疗总有效率明显高于对照组,且两年生存率明显高于对照组,差异均有统计学意义(P<0.05)。结论:DC-CIK细胞免疫治疗联合化疗治疗方案有利于提高中晚期非小细胞肺癌疾病近、远期治疗效果。

Objective:To discuss the effect of DC-CIK cell immunotherapy combined with chemotherapy in the treatment of middle and advanced non-small cell lung cancer.Methods:From January 2017 to January 2018,98 cases of patients with middle or advanced NSCLC were enrolled,they were randomly divided into two groups with 49 cases in each group.The control group received chemotherapy alone.The study group received DC-CIK cell immunotherapy combined with chemotherapy.The therapeutic effect and two-year survival rate were compared between the two groups.Results:The total effective rate of treatment in the study group was significantly higher than that in the control group,the two-year survival rate was significantly higher than that of the control group,the differences were statistically significant(P<0.05).Conclusion:DC-CIK cell immunotherapy combined with chemotherapy is beneficial to improve the short-term and long-term treatment of middle and advanced non-small cell lung cancer.